{ "schemaVersion": 2, "eyebrow": "Infectious Diseases", "title": "Staphylococcus Aureus Bacteremia Workup", "summary": "Treat every Staphylococcus aureus blood culture as a potential endovascular or metastatic infection: document clearance, identify and control the source, evaluate for endocarditis, and reserve 14-day therapy for patients meeting every uncomplicated-bacteremia criterion.", "seoDescription": "Physician workup of Staphylococcus aureus bacteremia: repeat cultures, source control, echocardiography, complication classification, and treatment duration.", "clinicalQuestion": "How should physicians evaluate Staphylococcus aureus bacteremia for clearance, source control, endocarditis, and metastatic infection?", "specialty": "Infectious Diseases", "audience": "U.S. physicians and medical trainees", "tags": [ "Staphylococcus aureus bacteremia", "SAB workup", "repeat blood cultures", "transesophageal echocardiography", "infective endocarditis", "source control", "complicated bacteremia" ], "keyTakeaways": [ "Obtain follow-up blood cultures within 48 hours of the initial set; persistent positivity beyond 48 hours after adequate therapy predicts complicated SAB and should trigger an intensified search for an endovascular or deep focus. [2][23]", "Do not label SAB uncomplicated unless all strict criteria are present: documented clearance, defervescence within 72 hours, no prosthetic material, exclusion of endocarditis, and no metastatic infection. [23][24]", "Echocardiographic exclusion of endocarditis is central to short-course management; TTE alone may be insufficient to rule out infective endocarditis, and guidelines have historically favored TEE or prolonged intravenous therapy. [12]", "Remove implicated intravascular access and obtain procedural source control when indicated; debridement, device removal, and incision and drainage are common necessary interventions in SAB. [23]", "Use 14 days of intravenous therapy only for uncomplicated SAB; endocarditis, metastatic infection, deep-tissue infection, or failure of uncomplicated criteria requires prolonged treatment, commonly 4-6 weeks depending on the syndrome. [2][3]" ], "sections": [ { "id": "first-day-actions", "eyebrow": "Immediate workup", "heading": "What to do when blood cultures grow S aureus", "intro": "Manage confirmed SAB as clinically consequential bacteremia until clearance and a treatable focus are established.", "paragraphs": [ "Start active antimicrobial therapy promptly, identify the organism and susceptibility profile, and pursue source control in parallel rather than after culture clearance. For bacteremia management, the core actions are timely appropriately dosed antibiotics, microbiologic identification, and source control wherever feasible. [3]", "Draw follow-up blood cultures within 48 hours after the initial culture set and continue cultures thereafter until the bloodstream is documented clear. A negative follow-up culture within this window is required for uncomplicated SAB; positive follow-up cultures more than 48 hours after adequate therapy identify patients at increased risk for complicated infection. [2][23][24]", "Immediately review all intravascular access, implanted prostheses, and sites of recent instrumentation. Remove a catheter implicated in catheter-associated SAB; source-control procedures commonly include removal of indwelling vascular access or prosthetic material, drainage of purulent collections, and debridement of osteomyelitis. [23]" ], "bullets": [ "Record the date and time of the first positive culture, first active antimicrobial dose, subsequent culture collection times, and first negative culture; these determine whether clearance occurred promptly and support duration decisions. [23][24]", "Treat persistent fever at 72 hours after the initial positive culture or persistent positive cultures beyond 48 hours after adequate therapy as escalation signals rather than as reasons to simply extend observation. [2]", "Consider infectious diseases consultation for SAB; adult studies associate consultation with improved management and outcomes. [3][5]" ], "subsections": [], "table": { "caption": "Early findings that change the workup intensity in Staphylococcus aureus bacteremia. [2][23][24]", "columns": [ "Finding", "Interpretation", "Next action" ], "rows": [ [ "Follow-up blood cultures negative within 48 hours", "One required element of uncomplicated SAB classification; does not alone exclude endocarditis or metastatic infection. [23][24]", "Complete echocardiographic and source assessment before considering a 14-day course. [23][24]" ], [ "Follow-up cultures remain positive >48 hours after adequate therapy", "Predictor of complicated SAB and possible endovascular, deep-tissue, or metastatic focus. [2]", "Repeat cultures to document clearance and intensify source-control and endocarditis evaluation. [2][23]" ], [ "Fever persists >72 hours", "Clinical predictor of complicated SAB. [2]", "Reassess antibiotic activity, source control, endocarditis, and metastatic infection. [2]" ], [ "Implanted prosthesis or retained infected device", "Fails uncomplicated-SAB criteria and can represent a persistent nidus. [23][24]", "Evaluate device involvement and remove implicated material when feasible. [23]" ] ] } }, { "id": "classify-complexity", "eyebrow": "Duration gate", "heading": "Classify uncomplicated versus complicated bacteremia only after the clearance workup", "intro": "The classification determines whether a short intravenous course is defensible.", "paragraphs": [ "Classify SAB as uncomplicated only when every criterion is met: endocarditis excluded by echocardiography; a catheter-associated source with catheter removal; no implanted prostheses; follow-up cultures obtained within 48 hours that remain negative; defervescence within 72 hours of effective therapy; and no metastatic infection. Any patient failing one or more criterion should be managed as complicated SAB. [23]", "A closely related IDSA-derived definition requires negative follow-up cultures obtained 2-4 days after the initial set, defervescence within 72 hours, no prosthetic material, and no endocarditis or metastatic infection. The practical implication is conservative: short-course treatment requires documented rapid clearance and a completed complication assessment, not an apparently well patient. [24]", "Community acquisition, delayed initiation of adequate therapy, fever persisting at 72 hours, and cultures remaining positive beyond 48 hours are predictors of complicated SAB. Their presence should lower the threshold for targeted imaging and extended intravenous treatment even before a discrete metastatic site is proven. [2]" ], "bullets": [ "Uncomplicated SAB: 2 weeks of intravenous antibiotics are considered sufficient. [2][3]", "Complicated SAB: infective endocarditis, metastatic foci, or deep-tissue infection requires a longer syndrome-directed course; 4-6 weeks may be required for complicated catheter-related infection, endocarditis, or osteomyelitis. [2][3]", "Do not use 14 days when an implanted prosthesis remains, clearance is delayed, fever persists beyond 72 hours, or echocardiography has not excluded endocarditis. [23][24]" ], "subsections": [], "table": { "caption": "Practical classification gate for SAB treatment duration. [2][3][23][24]", "columns": [ "Classification", "Required findings", "Treatment-duration consequence" ], "rows": [ [ "Uncomplicated SAB", "Rapid documented culture clearance, defervescence within 72 hours, no prosthetic material, no endocarditis, no metastatic infection, and catheter removal when catheter-associated. [23][24]", "Use 14 days of intravenous therapy. [2][3]" ], [ "Complicated SAB", "Endocarditis, metastatic focus, deep-tissue infection, persistent bacteremia, persistent fever, retained prosthetic material, or failure to meet any uncomplicated criterion. [2][23]", "Use prolonged intravenous therapy; 4-6 weeks may be required according to the established focus. [2][3]" ] ] } }, { "id": "endocarditis-evaluation", "eyebrow": "Cardiac focus", "heading": "When echocardiography changes management", "intro": "Endocarditis exclusion is required before classifying SAB as uncomplicated.", "paragraphs": [ "Obtain echocardiographic evaluation when considering a short-course regimen because infective endocarditis is therapeutically decisive and may lack classic peripheral findings early. Reported infective endocarditis prevalence in SAB has varied from 5% to 64% across study populations, underscoring that bedside appearance is not a reliable exclusion strategy. [11]", "A negative TTE may not be sufficiently sensitive to rule out infective endocarditis. Historical guideline approaches have therefore recommended TEE for all patients with SAB or, if TEE is not performed, management with prolonged intravenous therapy; TEE feasibility may be limited by availability, patient refusal, or critical illness. [12]", "Use a negative echocardiographic evaluation as one component of a complete uncomplicated-SAB determination, not as a substitute for documenting blood-culture clearance, defervescence, lack of prosthetic material, and absence of metastatic infection. [23][24]" ], "bullets": [ "Persistent bacteremia beyond 48 hours, fever beyond 72 hours, community acquisition, and delayed adequate therapy should heighten concern for complicated infection, including an endovascular focus. [2]", "If endocarditis is identified, do not apply the 14-day uncomplicated-SAB duration; international guideline recommendations for native-valve S aureus endocarditis range from 4 to 6 weeks, with IDSA cited as recommending 6 weeks. [2]" ], "subsections": [], "table": { "caption": "Echocardiography decision points in SAB. [12][23][24]", "columns": [ "Clinical question", "Action", "What the result changes" ], "rows": [ [ "Can this patient receive a 14-day uncomplicated-SAB course?", "Obtain echocardiography to exclude endocarditis as part of the strict uncomplicated classification. [23][24]", "A patient without echocardiographic exclusion does not meet uncomplicated criteria. [23]" ], [ "Is a negative TTE sufficient to rule out infective endocarditis?", "Recognize the limited sensitivity of TTE; use TEE when required to exclude endocarditis under the management strategy. [12]", "A negative TEE supports classification only when all other uncomplicated criteria are also met. [23][24]" ], [ "Endocarditis is present", "Treat as complicated infection and coordinate management around a prolonged intravenous regimen. [2][3]", "Duration moves from 14 days to a syndrome-directed prolonged course; cited guideline ranges are 4-6 weeks, with IDSA cited at 6 weeks for native-valve S aureus endocarditis. [2]" ] ] } }, { "id": "find-source-and-metastases", "eyebrow": "Source control", "heading": "Search for the source and metastatic focus", "intro": "Persistent bacteremia or an incomplete uncomplicated profile mandates active investigation for a remediable focus.", "paragraphs": [ "Direct the examination and imaging strategy to clinical findings, but do not defer source investigation in persistent SAB. Complicated SAB includes infective endocarditis, metastatic infection foci, and deep-tissue infection; persistent cultures and fever are clinical predictors that should trigger renewed examination for these entities. [2]", "For suspected catheter-associated SAB, determine whether the catheter is the likely source and remove it. Retained vascular devices and prosthetic material prevent uncomplicated classification; source-control procedures for SAB may include vascular-access removal, removal of infected prosthetic material, incision and drainage, and debridement of osteomyelitis. [23]", "When a metastatic focus is identified, align duration with the focal syndrome rather than with uncomplicated bacteremia. Endocarditis and osteomyelitis are examples for which 4-6 weeks may be required, and source control remains integral to cure. [3]" ], "bullets": [ "Re-examine for focal symptoms and signs after each persistently positive blood culture; a new localizing complaint should direct diagnostic imaging toward the corresponding deep focus. Persistent bacteremia is associated with metastatic foci and endocarditis in SAB classification frameworks. [2][23]", "If no removable source is evident and cultures remain positive, reassess antimicrobial activity and search for device-associated infection, abscess, and endocarditis; these mechanisms are described in persistent bloodstream infection. [16]", "Document whether prosthetic material is present even if it is not clearly infected, because any implanted prosthesis fails strict uncomplicated-SAB criteria. [23][24]" ], "subsections": [], "table": { "caption": "Source-control targets that alter SAB classification and management. [2][3][23]", "columns": [ "Potential focus", "Workup or intervention", "Management consequence" ], "rows": [ [ "Intravascular catheter", "Assess as a possible source; remove it when catheter-associated SAB is identified. [23]", "Removal is part of strict uncomplicated classification for catheter-associated SAB. [23]" ], [ "Prosthetic device or material", "Determine whether it is implicated and pursue removal when feasible for source control. [23]", "Presence of implanted prosthetic material excludes uncomplicated SAB. [23][24]" ], [ "Abscess or other drainable collection", "Perform incision and drainage or other procedural source control when indicated. [23]", "Failure to control a deep focus supports complicated-SAB management. [2][23]" ], [ "Osteomyelitis", "Obtain source control through debridement when indicated. [23]", "Requires prolonged therapy; 4-6 weeks may be required. [3]" ] ] } }, { "id": "antibiotic-review-and-escalation", "eyebrow": "Therapeutic reassessment", "heading": "Use microbiology and clearance kinetics to reassess therapy", "intro": "Antibiotic selection follows susceptibility, but persistent cultures require a source-control and endovascular reassessment.", "paragraphs": [ "For MSSA bacteremia, antistaphylococcal penicillins—nafcillin and oxacillin—are described as recommended definitive options. Cefazolin is frequently used because it is easier to administer and is associated with fewer adverse events; a large retrospective cohort found lower 30- and 90-day mortality with cefazolin than with antistaphylococcal penicillins, although observational comparisons do not resolve all regimen-selection questions. [7]", "For MRSA bacteremia, intravenous vancomycin is a usual initial treatment, with daptomycin described as an alternative in renal impairment. Do not interpret persistent bacteremia as an automatic indication for prolonged monotherapy: verify active therapy, remove or drain the source, evaluate for endocarditis and deep infection, and obtain serial cultures until clearance. [3][13][23]", "Cefazolin plus ertapenem has been reported in an 11-patient case series of persistent MSSA bacteremia lasting 4-9 days despite prior therapy; 8 of 9 evaluable episodes cleared cultures within 24 hours after combination initiation. This is limited observational rescue evidence, not a standard first-line regimen, and persistent SAB should first prompt aggressive investigation for inadequate source control or an occult endovascular focus. [8][23]" ], "bullets": [ "Use 14 days of intravenous treatment only after the full uncomplicated-SAB criteria are documented. [2][3][23]", "Treat infective endocarditis, osteomyelitis, and other complicated foci with a prolonged intravenous course; 4-6 weeks may be required. [2][3]", "Consider infectious diseases involvement when cultures persist, endocarditis is suspected, prosthetic material is present, or a prolonged regimen is required. [3][5]" ], "subsections": [], "table": { "caption": "Culture-kinetic response framework for SAB. [2][3][8][23]", "columns": [ "Status after effective therapy", "Interpretation", "Next step" ], "rows": [ [ "Cultures clear promptly and all uncomplicated criteria are satisfied", "Uncomplicated SAB. [23][24]", "Complete 14 days of intravenous therapy. [2][3]" ], [ "Cultures positive >48 hours", "Complicated-SAB predictor; consider endovascular, device-associated, or deep focus. [2]", "Continue serial cultures, reassess source control, and intensify endocarditis and metastatic-focus evaluation. [2][23]" ], [ "MSSA persists despite prior active treatment", "Persistent bacteremia requires reassessment; cefazolin plus ertapenem has only case-series rescue evidence. [8]", "Prioritize source-control and endovascular evaluation; consider specialist-directed regimen modification. [8][23]" ] ] } } ], "faq": [ { "question": "Can a patient with a negative follow-up blood culture be treated as uncomplicated SAB?", "answer": "No. A negative follow-up culture is necessary but insufficient. Uncomplicated SAB also requires defervescence within 72 hours, no prosthetic material, echocardiographic exclusion of endocarditis, and no metastatic infection; catheter-associated cases also require catheter removal. [23][24]" }, { "question": "When does persistent SAB require escalation?", "answer": "Escalate when follow-up cultures remain positive more than 48 hours after adequate therapy or fever persists beyond 72 hours. These findings predict complicated SAB and should prompt repeat cultures, source-control reassessment, and evaluation for endocarditis or metastatic infection. [2][23]" } ], "references": [ { "number": 1, "title": "Application Type NDA supplement", "detail": "www.fda.gov", "url": "https://www.fda.gov/media/108529/download", "authors": "www.fda.gov", "host": "www.fda.gov" }, { "number": 2, "title": "Safe shortening of antibiotic treatment duration for complicated Staphylococcus aureus bacteraemia (SAFE trial): protocol for a randomised, controlled, open-label, non-inferiority trial comparing 4 and 6 weeks of antibiotic treatment | BMJ Open", "detail": "bmjopen.bmj.com", "url": "https://bmjopen.bmj.com/content/13/4/e068295", "authors": "bmjopen.bmj.com", "host": "bmjopen.bmj.com" }, { "number": 3, "title": "Fever and infections in surgical intensive care", "detail": "tsaco.bmj.com", "url": "https://tsaco.bmj.com/content/9/1/e001303.full.pdf", "authors": "tsaco.bmj.com", "host": "tsaco.bmj.com" }, { "number": 4, "title": "Improving the management of Staphylococcus aureus ...", "detail": "bmjopenquality.bmj.com", "url": "https://bmjopenquality.bmj.com/content/2/1/u201154.w908", "authors": "bmjopenquality.bmj.com", "host": "bmjopenquality.bmj.com" }, { "number": 5, "title": "Impact of infectious diseases consultation on the management of ...", "detail": "bmjopen.bmj.com", "url": "https://bmjopen.bmj.com/content/4/7/e004659", "authors": "bmjopen.bmj.com", "host": "bmjopen.bmj.com" }, { "number": 6, "title": "Safe shortening of antibiotic treatment", "detail": "bmjopen.bmj.com", "url": "https://bmjopen.bmj.com/content/bmjopen/13/4/e068295.full.pdf", "authors": "bmjopen.bmj.com", "host": "bmjopen.bmj.com" }, { "number": 7, "title": "Cefazolin for Methicillin-Susceptible Staphylococcus aureus Bacteremia: Still Some Questions | NEJM Clinician", "detail": "clinician.nejm.org", "url": "https://clinician.nejm.org/cefazolin-methicillin-susceptible-staphylococcus-aureus-bacteremia-questions-nejm-jw.NA43870", "authors": "clinician.nejm.org", "host": "clinician.nejm.org" }, { "number": 8, "title": "Cefazolin plus Ertapenem for Persistent Methicillin-Susceptible Staphylococcus aureus Bacteremia | NEJM Clinician", "detail": "clinician.nejm.org", "url": "https://clinician.nejm.org/cefazolin-plus-ertapenem-persistent-methicillin-susceptible-staphylococcus-aureus-bacteremia-nejm-jw.NA50525?show-author=true&author-id=AU074", "authors": "clinician.nejm.org", "host": "clinician.nejm.org" }, { "number": 9, "title": "Staphylococcus aureus Bloodstream Infection: When Is ... - JACC", "detail": "www.jacc.org", "url": "https://www.jacc.org/doi/10.1016/j.jcmg.2015.02.025", "authors": "www.jacc.org", "host": "www.jacc.org" }, { "number": 10, "title": "Use of Transthoracic Echocardiography in the Management ... - JACC", "detail": "www.jacc.org", "url": "https://www.jacc.org/doi/abs/10.1016/j.jcmg.2015.02.027", "authors": "www.jacc.org", "host": "www.jacc.org" }, { "number": 11, "title": "Role of Echocardiography in Evaluation of Patients With